Leerink Partnrs Issues Positive Estimate for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($2.35) for the year, up from their previous estimate of ($2.68). The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.48) per share. Leerink Partnrs also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.68) EPS, FY2025 earnings at ($2.01) EPS, FY2026 earnings at ($1.82) EPS and FY2027 earnings at ($1.76) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.36.

Other equities research analysts also recently issued reports about the company. Guggenheim decreased their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. UBS Group decreased their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Wells Fargo & Company cut their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a report on Thursday. HC Wainwright decreased their price target on shares of Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Finally, Wedbush reissued a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, January 24th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Up 4.8 %

ZNTL opened at $1.74 on Monday. The company has a market capitalization of $123.99 million, a PE ratio of -0.70 and a beta of 1.86. The firm has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $3.26. Zentalis Pharmaceuticals has a 52 week low of $1.66 and a 52 week high of $18.07.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Savant Capital LLC purchased a new position in shares of Zentalis Pharmaceuticals during the 4th quarter worth about $72,000. SG Americas Securities LLC lifted its stake in Zentalis Pharmaceuticals by 115.6% in the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after purchasing an additional 30,240 shares during the last quarter. Barclays PLC boosted its position in shares of Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after buying an additional 11,748 shares during the period. XTX Topco Ltd grew its stake in shares of Zentalis Pharmaceuticals by 8.7% during the third quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock valued at $714,000 after buying an additional 15,597 shares during the last quarter. Finally, Quarry LP purchased a new stake in shares of Zentalis Pharmaceuticals in the third quarter worth approximately $55,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.